During the corresponding time, Orgenesis Inc recorded a revenue increase by 215.45 % year on year, sequentially revenue grew by 41.06 %. While revenue at the Orgenesis Inc 's corporate clients
Orgenesis Inc's Comment on Sales, Marketing and Customers
Octomera operates subsidiaries primarily focused on POCare services and cell-processing services across North America, Germany, Greece, and California. These subsidiaries include Orgenesis Maryland LLC, Tissue Genesis International LLC, Orgenesis Germany GmbH, Theracell Laboratories IKE, ORGS POC CA Inc, and Octo Services LLC. Subsidiaries in Korea, Israel, Australia, Belgium, and Romania are currently undergoing liquidation. The company is developing a pipeline of cell and gene therapies targeting cancer and other clinical needs, including personalized autologous cell therapies. Its immuno-oncology treatments include HiCAR-T for B-cell Acute Lymphoblastic Leukemia and B-cell lymphoma, T-LOOP and MDVAC for solid tumors, as well as therapies for metabolic diseases, cartilage defects, systemic ARDS, vascular disorders, and antiviral vaccines. These therapies are developed through proprietary research, joint ventures, and in-licensing agreements with biotech companies and research institutions, and are designed to integrate with advanced production platforms for manufacturing and delivery.
Orgenesis Inc’s Comment on Sales, Marketing and Customers
Octomera operates subsidiaries primarily focused on POCare services and cell-processing services across North America, Germany, Greece, and California. These subsidiaries include Orgenesis Maryland LLC, Tissue Genesis International LLC, Orgenesis Germany GmbH, Theracell Laboratories IKE, ORGS POC CA Inc, and Octo Services LLC. Subsidiaries in Korea, Israel, Australia, Belgium, and Romania are currently undergoing liquidation. The company is developing a pipeline of cell and gene therapies targeting cancer and other clinical needs, including personalized autologous cell therapies. Its immuno-oncology treatments include HiCAR-T for B-cell Acute Lymphoblastic Leukemia and B-cell lymphoma, T-LOOP and MDVAC for solid tumors, as well as therapies for metabolic diseases, cartilage defects, systemic ARDS, vascular disorders, and antiviral vaccines. These therapies are developed through proprietary research, joint ventures, and in-licensing agreements with biotech companies and research institutions, and are designed to integrate with advanced production platforms for manufacturing and delivery.
Sources:
Orgenesis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Orgenesis Inc’s corporate clients.
For your research, we’ve provided 9 tables on Orgenesis Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
78.39 %